Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 4;15(6):8363–8370. doi: 10.3892/ol.2018.8433

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Li et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 3. — Validation of cisplatin-resistant ovarian cancer-associated lncRNAs. (A) First the expression levels of dysregulated lncRNAs were validated in cisplatin-resistant and cisplatin-sensitive ovarian cancer tissues, and 8 lncRNAs were dysregulated in cisplatin-resistant ovarian cancer samples compared with cisplatin-sensitive ovarian cancer samples. (B) Subsequently, the expression levels of these 8 lncRNAs were assessed separately in cisplatin-resistant and cisplatin-sensitive ovarian cancer cells. Tissue and cell data demonstrated consistent results. Each experiment was repeated in triplicate. A positive value denotes the dysregulated lncRNAs that are upregulated, and a negative value means dysregulated lncRNAs that are downregulated. Error bars demonstrate that the differences between cisplatin-resistant ovarian cancer and cisplatin-sensitive ovarian cancer were statistically significant. *P<0.05 vs. cisplatin-sensitive ovarian cancer.